TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01791777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare Coaching
Description: This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare Coaching
Description: This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
Study: NCT04258657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel-albumin and S-1
Description: neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
Study: NCT00725543

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
Study: NCT03329729

Intervention type: OTHER
Intervention: Rosuvastatin
Description: Hyperlipidemic patients treated with rosuvastatin
Study: NCT01128114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate (Seroquel XR)
Description: Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
Study: NCT00020761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.
Study: NCT02803099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number-SR15-63-Z13-084).
Study: NCT02391077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Foreskin disinfection with Povidone-Iodine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Foreskin disinfection with Povidone-Iodine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic topical cream
Description: Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic topical cream
Description: Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 1%
Description: Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
Study: NCT01309698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Voglibose
Study: NCT02578498

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate intake
Description: Carbohydrate intake \< 50 gram
Study: NCT03121794

Intervention type: DEVICE
Intervention: ultrasound machine
Description: Regular ultrasound machine used at Cleveland Clinic

Intervention type: DEVICE
Intervention: ultrasound machine
Description: Regular ultrasound machine used at Cleveland Clinic

Intervention type: DEVICE
Intervention: ultrasound machine
Description: Regular ultrasound machine used at Cleveland Clinic
Study: NCT04685096

Intervention type: OTHER
Intervention: Test product creme
Description: twice daily application of creme containing 2% NMN

Intervention type: OTHER
Intervention: Test product creme
Description: twice daily application of creme containing 2% NMN

Intervention type: OTHER
Intervention: Reference creme
Description: twice daily application of reference creme

Intervention type: OTHER
Intervention: Reference creme
Description: twice daily application of reference creme
Study: NCT01615159

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior and lifestyle counseling
Description: 20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
Study: NCT03564132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yigansan
Description: Yigansan granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
Study: NCT00921206

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAX102
Description: 1 ug i.m. compared to 2 ug s.c.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAX102
Description: 1 ug i.m. compared to 2 ug s.c.
Study: NCT01017601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seneca Valley virus-001
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study: NCT03850990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo pill and no placebo pill
Description: The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo pill and no placebo pill
Description: The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
Study: NCT02578498

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low carbohydrate intake
Description: Carbohydrate intake \> 250 gram
Study: NCT01810276

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 400 mL of Saline will be given intravenously over 2 hours once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelets
Description: 2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
Study: NCT04697654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC19
Description: Hydroxychloroquine Liposome Inhalation Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC19
Description: Hydroxychloroquine Liposome Inhalation Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC19
Description: Hydroxychloroquine Liposome Inhalation Suspension

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: TLC19 Vehicle
Description: Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: TLC19 Vehicle
Description: Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: TLC19 Vehicle
Description: Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
Study: NCT00768885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision 1
Description: Currently marketed PureVision soft contact lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision 2
Description: Alternate design soft contact lens.
Study: NCT02083302

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCREAM Theater Dose 1
Description: Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Dose 1
Description: Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Dose 1
Description: Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Doses 2 & SCREAM Theater Dose 3
Description: Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Doses 2 & SCREAM Theater Dose 3
Description: Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCREAM Theater Dose 4
Description: Booster Session
Study: NCT02578888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy
Description: Palliative Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Palliative Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy + idiographic
Description: Ancillary studies
Study: NCT01607346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezogabine/retigabine
Description: Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
Study: NCT05180565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colovac
Description: A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
Study: NCT00675337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineum maintained
Description: infants maintained at the level of the perineum until umbilical cord clamping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal placement
Description: infants placed on the maternal abdomen prior to umbilical cord clamping
Study: NCT00560898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution
Description: Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
Study: NCT02731170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
Study: NCT01331135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
Study: NCT03782532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Controller Therapies (include prednisone/prednisolone)
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Controller Therapies (include prednisone/prednisolone)
Description: Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Reliever Therapies
Description: Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled
Study: NCT00913770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Description: Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Description: Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Initiation
Study: NCT02888275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Study: NCT03949738

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-infrared spectroscopy-based assessement of cerebral autoregulation.
Description: Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation.
Study: NCT00351936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03033927

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC isolocation and analysis
Description: Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
Study: NCT02950038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg given by mouth daily in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
Study: NCT02903420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
Study: NCT04140084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-life clinical meetings
Description: Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
Study: NCT01072578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
Study: NCT01523327

Intervention type: OTHER
Intervention: measuring protein creatinin ratio,serum uric acid
Description: A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method.

Intervention type: OTHER
Intervention: measuring protein creatinin ratio,serum uric acid
Description: A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method.